Aprea Therapeutics, Inc.
APRE
$0.90
-$0.03-3.26%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -80.99% | -62.76% | -34.08% | 33.26% | 157.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -80.99% | -62.76% | -34.08% | 33.26% | 157.60% |
| Cost of Revenue | -24.78% | -7.26% | 15.31% | 28.54% | 22.76% |
| Gross Profit | 14.04% | -2.14% | -24.24% | -27.89% | -11.60% |
| SG&A Expenses | 0.28% | -15.90% | -15.50% | -9.98% | -23.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.55% | -11.03% | 1.08% | 10.54% | -1.45% |
| Operating Income | 7.58% | 6.44% | -4.24% | -8.97% | 7.45% |
| Income Before Tax | 2.77% | 3.47% | -7.13% | -10.73% | 9.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.77% | 3.47% | -7.13% | -10.73% | 9.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.77% | 3.47% | -7.13% | -10.73% | 9.30% |
| EBIT | 7.58% | 6.44% | -4.24% | -8.97% | 7.45% |
| EBITDA | 7.59% | 6.45% | -4.22% | -8.92% | 7.55% |
| EPS Basic | 16.94% | 23.87% | 23.79% | 28.85% | 40.52% |
| Normalized Basic EPS | 16.93% | 23.86% | 23.79% | 28.85% | 40.52% |
| EPS Diluted | 16.94% | 23.87% | 23.79% | 28.85% | 40.52% |
| Normalized Diluted EPS | 16.93% | 23.86% | 23.79% | 28.85% | 40.52% |
| Average Basic Shares Outstanding | 18.65% | 23.18% | 36.14% | 54.69% | 52.31% |
| Average Diluted Shares Outstanding | 18.65% | 23.18% | 36.14% | 54.69% | 52.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |